Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity.

Zhao P, Sharir H, Kapur A, Cowan A, Geller EB, Adler MW, Seltzman HH, Reggio PH, Heynen-Genel S, Sauer M, Chung TD, Bai Y, Chen W, Caron MG, Barak LS, Abood ME.

Mol Pharmacol. 2010 Oct;78(4):560-8. doi: 10.1124/mol.110.066746. Epub 2010 Jul 22.

2.

Antagonists of GPR35 display high species ortholog selectivity and varying modes of action.

Jenkins L, Harries N, Lappin JE, MacKenzie AE, Neetoo-Isseljee Z, Southern C, McIver EG, Nicklin SA, Taylor DL, Milligan G.

J Pharmacol Exp Ther. 2012 Dec;343(3):683-95. doi: 10.1124/jpet.112.198945. Epub 2012 Sep 11.

3.

High-throughput identification and characterization of novel, species-selective GPR35 agonists.

Neetoo-Isseljee Z, MacKenzie AE, Southern C, Jerman J, McIver EG, Harries N, Taylor DL, Milligan G.

J Pharmacol Exp Ther. 2013 Mar;344(3):568-78. doi: 10.1124/jpet.112.201798. Epub 2012 Dec 21.

4.

Agonist activation of the G protein-coupled receptor GPR35 involves transmembrane domain III and is transduced via Gα₁₃ and β-arrestin-2.

Jenkins L, Alvarez-Curto E, Campbell K, de Munnik S, Canals M, Schlyer S, Milligan G.

Br J Pharmacol. 2011 Feb;162(3):733-48. doi: 10.1111/j.1476-5381.2010.01082.x.

5.

Identification of novel species-selective agonists of the G-protein-coupled receptor GPR35 that promote recruitment of β-arrestin-2 and activate Gα13.

Jenkins L, Brea J, Smith NJ, Hudson BD, Reilly G, Bryant NJ, Castro M, Loza MI, Milligan G.

Biochem J. 2010 Dec 15;432(3):451-9. doi: 10.1042/BJ20101287.

PMID:
20919992
6.

Crucial positively charged residues for ligand activation of the GPR35 receptor.

Zhao P, Lane TR, Gao HG, Hurst DP, Kotsikorou E, Le L, Brailoiu E, Reggio PH, Abood ME.

J Biol Chem. 2014 Feb 7;289(6):3625-38. doi: 10.1074/jbc.M113.508382. Epub 2013 Dec 17.

7.

G-protein coupled receptor 35 (GPR35) activation and inflammatory pain: Studies on the antinociceptive effects of kynurenic acid and zaprinast.

Cosi C, Mannaioni G, Cozzi A, Carlà V, Sili M, Cavone L, Maratea D, Moroni F.

Neuropharmacology. 2011 Jun;60(7-8):1227-31. doi: 10.1016/j.neuropharm.2010.11.014. Epub 2010 Nov 24.

PMID:
21110987
8.

Tyrphostin analogs are GPR35 agonists.

Deng H, Hu H, Fang Y.

FEBS Lett. 2011 Jun 23;585(12):1957-62. doi: 10.1016/j.febslet.2011.05.026. Epub 2011 May 17.

9.

GPR35 is a novel lysophosphatidic acid receptor.

Oka S, Ota R, Shima M, Yamashita A, Sugiura T.

Biochem Biophys Res Commun. 2010 Apr 30;395(2):232-7. doi: 10.1016/j.bbrc.2010.03.169. Epub 2010 Mar 31.

PMID:
20361937
10.

Label-free phenotypic profiling identified D-luciferin as a GPR35 agonist.

Hu H, Deng H, Fang Y.

PLoS One. 2012;7(4):e34934. doi: 10.1371/journal.pone.0034934. Epub 2012 Apr 12.

11.

Discovery of 2-(4-methylfuran-2(5H)-ylidene)malononitrile and thieno[3,2-b]thiophene-2-carboxylic acid derivatives as G protein-coupled receptor 35 (GPR35) agonists.

Deng H, Hu H, He M, Hu J, Niu W, Ferrie AM, Fang Y.

J Med Chem. 2011 Oct 27;54(20):7385-96. doi: 10.1021/jm200999f. Epub 2011 Oct 4.

12.

Mind your salts: when the inactive constituent isn't.

Neubig RR.

Mol Pharmacol. 2010 Oct;78(4):558-9. doi: 10.1124/mol.110.067645. Epub 2010 Jul 22. Review.

13.

Thieno[3,2-b]thiophene-2-carboxylic acid derivatives as GPR35 agonists.

Deng H, Hu J, Hu H, He M, Fang Y.

Bioorg Med Chem Lett. 2012 Jun 15;22(12):4148-52. doi: 10.1016/j.bmcl.2012.04.057. Epub 2012 Apr 21.

PMID:
22572579
14.

The pharmacology of TUG-891, a potent and selective agonist of the free fatty acid receptor 4 (FFA4/GPR120), demonstrates both potential opportunity and possible challenges to therapeutic agonism.

Hudson BD, Shimpukade B, Mackenzie AE, Butcher AJ, Pediani JD, Christiansen E, Heathcote H, Tobin AB, Ulven T, Milligan G.

Mol Pharmacol. 2013 Nov;84(5):710-25. doi: 10.1124/mol.113.087783. Epub 2013 Aug 26.

15.
16.

5-Nitro-2-(3-phenylpropylamino)benzoic acid is a GPR35 agonist.

Taniguchi Y, Tonai-Kachi H, Shinjo K.

Pharmacology. 2008;82(4):245-9. doi: 10.1159/000157625. Epub 2008 Sep 26.

PMID:
18818509
17.

Discovery of novel FFA4 (GPR120) receptor agonists with β-arrestin2-biased characteristics.

Li A, Yang D, Zhu M, Tsai KC, Xiao KH, Yu X, Sun J, Du L.

Future Med Chem. 2015;7(18):2429-37. doi: 10.4155/fmc.15.160. Epub 2015 Dec 14.

PMID:
26653412
18.

beta-Arrestin recruitment assay for the identification of agonists of the sphingosine 1-phosphate receptor EDG1.

van Der Lee MM, Bras M, van Koppen CJ, Zaman GJ.

J Biomol Screen. 2008 Dec;13(10):986-98. doi: 10.1177/1087057108326144. Epub 2008 Nov 25.

PMID:
19036707
19.

G protein-coupled receptor 35 contributes to mucosal repair in mice via migration of colonic epithelial cells.

Tsukahara T, Hamouda N, Utsumi D, Matsumoto K, Amagase K, Kato S.

Pharmacol Res. 2017 Jun 23;123:27-39. doi: 10.1016/j.phrs.2017.06.009. [Epub ahead of print]

PMID:
28648739
20.

Supplemental Content

Support Center